⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9847517 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL31268132 | 0.95 | — | — | |
| SCHEMBL19343233 | 0.82 | — | — | |
| SCHEMBL5566152 | 0.79 | — | — | |
| SCHEMBL84159 | 0.79 | — | — | |
| SCHEMBL988689 | 0.79 | — | — | |
| SCHEMBL3439164 | 0.79 | — | — | |
| SCHEMBL169344 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL25235322 | 0.76 | — | — | |
| SCHEMBL20694112 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4733297-A1 | INTEGRIN-INHIBITING SMALL MOLECULE COMPOUND | Antibody Therapeutics, Inc. (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-4605121-A1 | DELIVERY PARTICLES BASED ON AMINE-THIOL-ENE CONJUGATES AND DERIVATIVES | Encapsys, LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024262620-A1 | INTEGRIN-INHIBITING SMALL MOLECULE COMPOUND | 株式会社抗体医学研究所 | 2024-12-26 | — | — | WO | disclosed |
| WO-2024086501-A1 | DELIVERY PARTICLES BASED ON AMINE-THIOL-ENE CONJUGATES AND DERIVATIVES | ENCAPSYS, LLC (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-20 | — | — | US | disclosed |
| CN-115348861-A | Alpha-5 beta-1 inhibitors | 加利福尼亚大学董事会 | 2022-11-15 | — | — | CN | disclosed |
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | disclosed |
| WO-2004060376-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPRATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060376-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPRATION (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040116472-A1 | Lactone integrin antagonists | PHARMACIA CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-6720327-B2 | ALPHA V BETA 5 (VITRONECTIN RECEPTOR) ANTAGONISTS FOR TREATMENT OF PROLIFERATIVE DISEASE SUCH A TUMOR METASTASIS, ANGIOGENESIS, RESTENOSIS | PHARMACIA CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040019206-A1 | Lactone integrin antagonists | RUMINISKI PETER (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1320363-A4 | LACTONE INTEGRIN ANTAGONISTS | PHARMACIA CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1320363-A1 | LACTONE INTEGRIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20020045645-A1 | Lactone integrin antagonists | PHARMACIA CORPORATION | 2002-04-18 | — | — | US | disclosed |
| WO-2002026227-A1 | LACTONE INTEGRIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2002-04-04 | — | — | WO | disclosed |